CC BY-NC-ND 4.0 · Eur J Dent 2018; 12(01): 036-042
DOI: 10.4103/ejd.ejd_54_17
Original Article
Dental Investigation Society

Comparison of osteoclastogenesis and local invasiveness of ameloblastoma and keratocystic odontogenic tumor

Natheer H. Al-Rawi
1   Department of Oral and Craniofacial Health Sciences, College of Dental Medicine, University of Sharjah, Sharjah, United Arab Emirates
,
Ammar K. Al-Siraj
2   Department of Oral Diagnosis, College of Dentistry, University of Baghdad, Baghdad, Iraq
,
Ahlam H. Majeed
2   Department of Oral Diagnosis, College of Dentistry, University of Baghdad, Baghdad, Iraq
› Author Affiliations
Further Information

Publication History

Publication Date:
13 September 2019 (online)

Abstract:

Objectives The aim of this study was to compare the expression of receptor-activated nuclear factor kappa B (RANK) with its ligand (RANKL) and matrix metalloproteinase-2 (MMP2) in solid/multicystic ameloblastomas (ABs) and keratocystic odontogenic tumors (KOTs). Materials and Methods: The expression of MMP2, RANK, and RANKL molecules was evaluated in 13 ABs and 14 KOTs by immunohistochemistry. The expressions were calculated in the odontogenic epithelial cells as well as the stromal cells. Results: Odontogenic epithelia of AB expressed MMP2, RANK, and RANKL significantly higher than that of KOTs (P < 0.05). The expression of MMP2, RANK, and RANKL was highest in plexiform subtype (79.9%, 81.08%, and 65.1%, respectively). KOTs without daughter epithelia nests expressed both MMP2 and RANK the least (56.06% and 47.5%, respectively). Stromal cells, on the other hand, expressed similar MMP2 pattern in odontogenic epithelia of both AB and KOT. RANKL was expressed weaker in the stromal cells of both lesions. Conclusion: Invasive biological and osteolytic behaviors of both lesions were evaluated in this study. It was found to be more in AB than keratocystic odontogenic. A significant expression of MMP2, RANK, and RANKL in both KOTs associated with microcyst and plexiform type AB as well.

 
  • REFERENCES

  • 1 Mendenhall WM, Werning JW, Fernandes R, Malyapa RS, Mendenhall NP. Ameloblastoma. Am J Clin Oncol 2007; 30: 645-8
  • 2 Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology and Genetics of Head and Neck Tumours: Odontogenic Tumours. World Health Organization Classification of Tumours; Ch. 6. Lyon: IARC Press: 2005: 283-328
  • 3 Lacy DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclasts differentiation and activation. Cell 1998; 93: 165-76
  • 4 Andrade FR, Sousa DP, Mendonça EF, Silva TA, Lara VS, Batista AC. et al. Expression of bone resorption regulators (RANK, RANKL, and OPG) in odontogenic tumors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 106: 548-55
  • 5 da Silva TA, Batista AC, Mendonça EF, Leles CR, Fukada S, Cunha FQ. et al. Comparative expression of RANK, RANKL, and OPG in keratocystic odontogenic tumors, ameloblastomas, and dentigerous cysts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 105: 333-41
  • 6 Sandra F, Hendarmin L, Kukita T, Nakao Y, Nakamura N, Nakamura S. et al. Ameloblastoma induces osteoclastogenesis: A possible role of ameloblastoma in expanding in the bone. Oral Oncol 2005; 41: 637-44
  • 7 Docherty AJ, Murphy G. The tissue metalloproteinase family and the inhibitor TIMP: A study using cDNAs and recombinant proteins. Ann Rheum Dis 1990; 49 (Suppl. 01) 469-79
  • 8 Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res 2003; 92: 827-39
  • 9 Tekkesin MS, Mutlu S, Olgac V. The role of RANK/RANKL/OPG signalling pathways in osteoclastogenesis in odontogenic keratocysts, radicular cysts, and ameloblastomas. Head Neck Pathol 2011; 5: 248-53
  • 10 Creemers JW, Ines Dominguez D, Plets E, Serneels L, Taylor NA, Multhaup G. et al. Processing of beta-secretase by furin and other members of the proprotein convertase family. J Biol Chem 2001; 276: 4211-7
  • 11 Poulsom R, Pignatelli M, Stetler-Stevenson WG, Liotta LA, Wright PA, Jeffery RE. et al. Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol 1992; 141: 389-96
  • 12 Zhang B, Zhang J, Huang HZ, Chen WL, Tao Q, Zeng DL. et al. Inhibition of ameloblastoma invasion in vitro and in vivo by inhibitor of metalloproteinase-2 activity. J Oral Pathol Med 2009; 38: 731-6
  • 13 Zhong M, Han YP, Wang J, Li ZJ, Bao G, Yue YL. et al. Expression of matrix metalloproteinases and tissue inhibitor of metalloproteinase in ameloblastoma. Shanghai Kou Qiang Yi Xue 2003; 12: 427-31
  • 14 Wang A, Zhang B, Huang H, Zhang L, Zeng D, Tao Q. et al. Suppression of local invasion of ameloblastoma by inhibition of matrix metalloproteinase-2 in vitro . BMC Cancer 2008; 8: 182
  • 15 Khalifa GA, Shokier HM, Abo-Hager EA. Evaluation of neoplastic nature of keratocystic odontogenic tumor versus ameloblastoma. J Egypt Natl Canc Inst 2010; 22: 61-72
  • 16 Meghji S, Henderson B, Bando Y, Harris M. Interleukin-1: The principal osteolytic cytokine produced by keratocysts. Arch Oral Biol 1992; 37: 935-43
  • 17 Wahlgren J, Väänänen A, Teronen O, Sorsa T, Pirilä E, Hietanen J. et al. Laminin-5 gamma 2 chain is colocalized with gelatinase-A (MMP-2) and collagenase-3 (MMP-13) in odontogenic keratocysts. J Oral Pathol Med 2003; 32: 100-7
  • 18 Zhong M, Li ZJ, Wang J, Yue YL, Bao G. The study of the invasive biologic behavior of ameloblastoma. Zhonghua Kou Qiang Yi Xue Za Zhi 2004; 39: 45-8
  • 19 Kumamoto H, Yamauchi K, Yoshida M, Ooya K. Immunohistochemical detection of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in ameloblastomas. J Oral Pathol Med 2003; 32: 114-20
  • 20 Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516
  • 21 Page G, Miossec P. RANK and RANKL expression as markers of dendritic cell-T cell interactions in paired samples of rheumatoid synovium and lymph nodes. Arthritis Rheum 2005; 52: 2307-12
  • 22 Stejskal D, Bartek J, Pastorková R, Růzicka V, Oral I, Horalík D. et al. Osteoprotegerin, RANK, RANKL. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2001; 145: 61-4
  • 23 Tay JY, Bay BH, Yeo JF, Harris M, Meghji S, Dheen ST. et al. Identification of RANKL in osteolytic lesions of the facial skeleton. J Dent Res 2004; 83: 349-53
  • 24 Kanzaki H, Chiba M, Shimizu Y, Mitani H. Dual regulation of osteoclast differentiation by periodontal ligament cells through RANKL stimulation and OPG inhibition. J Dent Res 2001; 80: 887-91
  • 25 Oka S, Kubota Y, Yamashiro T, Ogata S, Ninomiya T, Ito S. et al. Effects of positive pressure in odontogenic keratocysts. J Dent Res 2005; 84: 913-8
  • 26 Qian Y, Huang HZ. The role of Rankl and MMP-9 in the bone resorption caused by ameloblastoma. J Oral Pathol Med 2010; 39: 592-8
  • 27 Kumamoto H, Ohki K, Ooya K. Expression of p63 and p73 in ameloblastomas. J Oral Pathol Med 2005; 34: 220-6
  • 28 Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337-42